This article is by Lauren Tappan.
Bisphosphonates, which are typically used to prevent osteoporosis, are some of the most prescribed drugs. They are known to increase the risk of inflammatory eye diseases such as scleritis, uveitis, and optic neuritis, and their pro-inflammatory properties may account for this increased risk as well as the flu-like symptoms that have been reported as adverse effects of their use.
The appearance of flu-like symptoms after use of the injected bisphosphonate zolendronic acid (Reclast/Novartis) has been attributed to the release of inflammatory mediators such as C-reactive protein. This common marker of systemic inflammation has been associated with coronary artery disease and implicated in the development of age-related macular degeneration (AMD), including its neovascular (wet) form. –
This article is from http://www.wkyc.com/
Steve McMillin learned at age 32 he had Retinitis Pigmentosa, a genetic disease that would stop his retinas from functioning. By 49, he was completely blind.
He kept up to date on new research emerging and heard about the bionic retina, a retinal prosthesis device that sends electrical impulses to the remaining retinal cells and restores limited vision patterns.
“They take the lens off the top of your eye, remove the vitrious fluid and install a six-by-ten grid of electrodes in your eye,” said McMillin.
Last June, Steve became the twentieth patient in the US to receive the device when he had his surgery at Cleveland Clinic’s Cole Eye Institute
He can see vague, black and white images.
“So you can tell, well, there’s the road, there’s a driveway, there’s a mailbox, there’s a shrub. Am I veering off track? It’s another tool in the toolbox and, boy, it’s a big tool,” McMillin says.
When asked what the most important thing he saw after ten years of blindness was, he replied, “To go out in the moonlight and see your wife’s face.”
Read more at on.wkyc.com/29e6JTB.
Your change in vision status is a good time to rethink how technology can help you maintain your independence. An accessible computer can be one of your most valuable tools. Consider just a few of the tasks of daily living you will be able to accomplish independently using a personal computer:
- Keeping in Touch
- Keeping up with the News
- Handling Finances
- Saving Money
- Staying Entertained
- Reading your mail and other important documents
Computers use special programs, operating systems, and applications, to perform tasks as varied as solving advanced mathematics problems to displaying your grandchild’s latest artwork on a screen. Though it might seem that the majority of a computer’s functionality relies on vision, the truth is that text lies behind most of what a computer does, from calculations to web pages. And since text can be output in an audible format, under the right circumstances and with the right training, computers are actually highly accessible to people with visual impairments. Think of it this way: When you type an “A” on a computer keyboard, you can either see that letter show up on the screen or hear it read aloud.
For more info:
The following is by Lauren Tappan.
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology.
Anti-vascular endothelial growth factor (VEGF) medicines have revolutionized DME treatment. A recent randomized clinical trial comparing anti-VEGF agents for patients with decreased vision from DME found that at 1 year aflibercept (2.0 mg) achieved better visual outcomes than repackaged (compounded) bevacizumab (1.25 mg) or ranibizumab (0.3 mg); the worse the starting vision, the greater the treatment benefit with aflibercept.
These agents also vary substantially in cost. On the basis of 2015 costs, aflibercept was $1,850, ranibizumab, $1,170, and repackaged (compounded) bevacizumab, approximately $60 per dose. Considering that these medicines may be given 9 to 11 times in the first year of treatment and, on average, 17 times during 5 years, total costs can be substantial. In 2010, when these intravitreous agents were being used predominantly for age-related macular degeneration, ophthalmologic use of VEGF therapy cost approximately $2 billion or one-sixth of the entire Medicare Part B drug budget. In 2013, Medicare Part B expenditures for aflibercept and ranibizumab alone totaled $2.5 billion.
For more info:
This news is from Lauren Tappan:
Four Japanese institutions will collaborate on transplanting tissue grown from induced pluripotent stem cells taken from donors into patients suffering from age-related macular degeneration, a hard-to-cure eye disease.
The initiative, announced Monday, will break new ground in that the cost of transplanting iPS-derived tissue will be significantly reduced by using stocked cells provided by donors, instead of using the patients’ own cells as in a previous case involving a sufferer of the same disease.
Under the partnership agreed on May 30, Kyoto University will provide iPS cells resistant to immunological rejection in the treatment and the government-affiliated Riken research institute will grow them into retinal cells. Osaka University and the Kobe City Medical Center General Hospital will implant these cells into patients as early as the first half of 2017.
The cost is approx. $1 million.